TMPRSS2-ERG and PTEN loss in prostate cancer - PubMed (original) (raw)

Comment

TMPRSS2-ERG and PTEN loss in prostate cancer

Jeremy A Squire. Nat Genet. 2009 May.

Abstract

Two studies show that the common recurrent gene fusion between TMPRSS2 and ERG promotes prostate cancer in both mouse and humans when PTEN is concurrently lost. In human prostate cancer, the presence of both these aberrations may be indicative of poor prognosis, suggesting that preclinical therapeutic research should target both of these pathways.

PubMed Disclaimer

Comment on

• Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
  King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL. King JC, et al. Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26. Nat Genet. 2009. PMID: 19396167 Free PMC article.
• Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
  Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Carver BS, et al. Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26. Nat Genet. 2009. PMID: 19396168 Free PMC article.

Similar articles

• Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
  Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C. Minner S, et al. Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14. Prostate. 2019. PMID: 30430607
• Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
  Hernández S, Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Salido M, Fumadó L, Serrano L, Cecchini L, Serrano S, Lloreta J. Hernández S, et al. Prostate. 2016 Jun;76(9):854-65. doi: 10.1002/pros.23176. Epub 2016 Mar 9. Prostate. 2016. PMID: 26959281
• Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
  Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Carver BS, et al. Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26. Nat Genet. 2009. PMID: 19396168 Free PMC article.
• Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
  Shah RB. Shah RB. Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Adv Anat Pathol. 2013. PMID: 23399797 Review.
• Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
  Sarker D, Reid AH, Yap TA, de Bono JS. Sarker D, et al. Clin Cancer Res. 2009 Aug 1;15(15):4799-805. doi: 10.1158/1078-0432.CCR-08-0125. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638457 Review.

Cited by

• Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis.
  Zhang L, Shao L, Creighton CJ, Zhang Y, Xin L, Ittmann M, Wang J. Zhang L, et al. Oncotarget. 2015 Mar 20;6(8):6281-94. doi: 10.18632/oncotarget.3366. Oncotarget. 2015. PMID: 25749044 Free PMC article.
• Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
  Sreenath TL, Dobi A, Petrovics G, Srivastava S. Sreenath TL, et al. J Carcinog. 2011;10:37. doi: 10.4103/1477-3163.91122. Epub 2011 Dec 31. J Carcinog. 2011. PMID: 22279422 Free PMC article.
• Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.
  Nitschke K, Erben P, Waldbillig F, Abdelhadi A, Weis CA, Gottschalt M, Wahby S, Nuhn P, Boutros M, Michel MS, von Hardenberg J, Worst TS. Nitschke K, et al. World J Urol. 2020 Mar;38(3):637-645. doi: 10.1007/s00345-019-02651-8. Epub 2019 Jan 30. World J Urol. 2020. PMID: 30701334
• ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.
  Nagle RB, Algotar AM, Cortez CC, Smith K, Jones C, Sathyanarayana UG, Yun S, Riley J, Nagy D, Dittamore R, Dalkin B, Brosh L, Pestano G. Nagle RB, et al. Prostate. 2013 Aug;73(11):1233-40. doi: 10.1002/pros.22675. Epub 2013 May 7. Prostate. 2013. PMID: 23653096 Free PMC article.
• Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling.
  Lin HP, Lin CY, Liu CC, Su LC, Huo C, Kuo YY, Tseng JC, Hsu JM, Chen CK, Chuu CP. Lin HP, et al. Int J Mol Sci. 2013 Mar 6;14(3):5264-83. doi: 10.3390/ijms14035264. Int J Mol Sci. 2013. PMID: 23466879 Free PMC article.

References

1. 1. Nat Genet. 2009 May;41(5):619-24 - PubMed
2. 1. Nat Genet. 2009 May;41(5):524-6 - PubMed
3. 1. Cancer Res. 2004 Mar 15;64(6):2270-305 - PubMed
4. 1. N Engl J Med. 2009 Mar 26;360(13):e18 - PubMed
5. 1. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11563-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program